Clinical Trials Logo

Dyslipidemias clinical trials

View clinical trials related to Dyslipidemias.

Filter by:

NCT ID: NCT03805776 Not yet recruiting - Dyslipidemias Clinical Trials

Intermittent Fasting in Dyslipidemia

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

World Health Organization report notifies of the escalating global burden of cardiovascular diseases (CVD), projecting that it will become the major worldwide cause of death and disability by 2020. The South Asian countries have the highest rates of CVD globally. It is widely acknowledged that South Asians have 40-60% higher risk of CVD linked to mortality, compared with other populations. Multiple human population studies have established the concentration of high density lipoprotein (HDL) cholesterol as an independent, inverse predictor of the risk of having a cardiovascular event. Furthermore, HDLs have several well-documented functions with the potential to protect against cardiovascular disease. This study trial is designed to find out the role of intermittent fasting to improve the dyslipidemia and particularly increase the levels of HDL in general population. Investigators expect that the intermittent fasting will significantly enhance the level of HDL and reduce cardiovascular events in general population.

NCT ID: NCT03805139 Not yet recruiting - Dyslipidemias Clinical Trials

Role of Ajwa Derived Polyphenols in Dyslipidaemias

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

World Health Organization report notifies of the escalating global burden of cardiovascular diseases (CVD), projecting that it will become the major worldwide cause of death and disability by 2020. The South Asian countries have the highest rates of CVD globally. It is widely acknowledged that South Asians have 40-60% higher risk of CVD linked to mortality, compared with other populations. Multiple human population studies have established the concentration of high density lipoprotein (HDL) cholesterol as an independent, inverse predictor of the risk of having a cardiovascular event. Furthermore, HDLs have several well-documented functions with the potential to protect against cardiovascular disease. This study trial is designed to find out the role of alternative medicine such as functional food to improve the dyslipidemia and particularly increase the levels of HDL in general population. We expect that the use of Ajwa dates will significantly enhance the level of HDL and reduce cardiovascular events in general population.

NCT ID: NCT03804775 Completed - Dyslipidemias Clinical Trials

Comparative Analysis of Serum Lipid Profiles in Patients With and Without Gallstones

Start date: August 1, 2017
Phase:
Study type: Observational

Gallbladder disease is one of the most common diseases of the gastrointestinal tract. Various studies have shown an association between gallstones and an alteration in the serum lipids. The objective of this study will be to compare serum lipid profile of gallstone patients with the controls.

NCT ID: NCT03799185 Recruiting - Atherosclerosis Clinical Trials

Dyslipidemia Prevalence, Perception, Treatment, and Awareness in the Tunisian Population

ATERASurvey
Start date: January 4, 2016
Phase:
Study type: Observational [Patient Registry]

ATERA Survey is a national cross sectional observational study, aiming to determine the prevalence of dyslipidemia and other conventional risk factors for CHD (Coronary Heart Disease), the relationship between environmental and lifestyle factors with dyslipidemia, the perception and the knowledge of cardiovascular risk factors by the population, and above all, to strengthen the national strategy for primary and secondary prevention against coronary heart disease.

NCT ID: NCT03795038 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONET vs. the Whole Blood Apheresis System DALI

DIAMOND-2018
Start date: January 15, 2019
Phase: N/A
Study type: Interventional

The clinical Investigation will be performed to compare the safety and effectiveness of the CE certified and established lipoprotein apheresis systems MONET vs. DALI and DIAMED vs. DALI for optimizing the individual therapy of patients with severe dyslipidemia using established and novel efficacy parameters.

NCT ID: NCT03794531 Enrolling by invitation - Obesity Clinical Trials

Psychosocial, Environmental, and Chronic Disease Trends in Puerto Rico

PROSPECT
Start date: December 17, 2018
Phase:
Study type: Observational

The overall goal is to identify trends and longitudinal associations in psychosocial, food-related, and cardiometabolic risk factors that can guide public health priorities and future research needs aimed at reducing cardiovascular-related disparities in Puerto Rico. To this end, investigators will establish 'PROSPECT: Puerto Rico Observational Study of Psychosocial, Environmental, and Chronic disease Trends', an island-wide, longitudinal population cohort of 2,000 adults (30-75 years) in PR recruited with a multi-frame sampling of probabilistic plus community approaches, and assessed in a network of several partner clinics across the island. The study will collect comprehensive data on multiple psychosocial, dietary, and food-related factors, CVD biological markers, and medical record data, with follow-up at 2-years, and will assess variations by urban-rural area and by timing before-after Maria.

NCT ID: NCT03773315 Recruiting - Dyslipidemias Clinical Trials

Ulmus Macrocarpa Hance Extract and Lipid Profile

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of the Ulmus Macrocarpa Hance extract on lipid profile in adults with dyslipidemia for 12 weeks.

NCT ID: NCT03750760 Not yet recruiting - Clinical trials for Myocardial Infarction

Early Alirocumab to Reduce LDL-C in Myocardial Infarction

EARLY
Start date: January 2019
Phase: Phase 4
Study type: Interventional

The EARLY trial is a phase IV, investigator initiated, international, multicentre study that will investigate if early use of alirocumab 150mg plus atorvastatin 80mg (enhanced care) will have a greater effect than atorvastatin 80mg (standard care) on the reduction of LDL-C at 2-weeks after a myocardial infarction (MI), in patients who start treatment within 24 hours of symptom onset. A secondary goal is to assess the effects of enhanced care when compared to standard care which is either atorvastatin alone or atorvastatin plus ezetimibe, (the latter added at 4 weeks if LDL-C is ≥ 70mg/dL (1.8mmol/L), on the proportion of patients achieving an LDL-C goal of < 50mg/dL (1.29 mmol/L) at 7 weeks after an MI.

NCT ID: NCT03747224 Recruiting - Clinical trials for Hypertriglyceridemia

Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

Start date: January 7, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetcs and pharmacodynamics of single- and multiple doses of ARO-ANG3 in healthy adult volunteers and in dyslipidemic patients including familial hypercholesterolemia and severe hypertriglyceridemia.

NCT ID: NCT03742544 Enrolling by invitation - Hypertension Clinical Trials

Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy

Start date: June 23, 2015
Phase:
Study type: Observational

Post-marketing surveillance of Telostop TAB (Telmisartan/Rosuvastatin)